Abstract
PCSK9 inhibitors (Proprotein convertase subtilisin-kexin9 inhibitors) not only have a good lipid-lowering effect but also have the effects of improving cardiovascular outcome, anti-inflammation, reducing oxidative stress and improving vascular endothelium. In recent years, the continuous research and development of PCSK9 inhibitors have provided new ideas for the treatment of cardiovascular diseases. This article reviews the multiple action mechanisms of PCSK9 inhibitors and their research in kidney disease and cerebrovascular diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
